{'fraction_non_alphanumeric': 0.015027322404371584, 'fraction_numerical': 0.001366120218579235, 'mean_word_length': 6.635416666666667, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
An analysis of glucocorticoid receptor‐mediated gene expression in BEAS‐2B human airway epithelial cells identifies distinct, ligand‐directed, transcription profiles with implications for asthma therapeutics

International asthma guidelines recommend that inhaled glucocorticoids be used as a monotherapy in all patients with mild to moderate disease because of their ability to suppress airways inflammation. Current evidence suggests that the therapeutic benefit of glucocorticoids is due to the transactivation and transrepression of anti‐inflammatory and pro‐inflammatory genes respectively. However, the extent to which clinically relevant glucocorticoids are equivalent in their ability to modulate gene expression is unclear.